PPARgamma antibody | knockout validation | Santa Cruz Biotechnology sc-7273

This is a knockout-validated antibody summary, based on the publication "Impact of targeted PPARγ disruption on bone remodeling", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

PPARgamma antibody | knockout validation | Santa Cruz Biotechnology sc-7273 figure 1
Figure 1. Western blot showing PPARγ protein expression in BMSCs from control floxed (PPARγfl/fl) and PPARγ cKO mice BMSCs. From [1].
Antibody information

Mouse monoclonal IgG1 (kappa light chain)

Company: Santa Cruz Biotechnology

Antibody: PPARgamma

Catalog number: sc-7273

Summary: Mouse monoclonal IgG1 (kappa light chain) against an epitope mapping between amino acids 486-505 at the C-terminus of human PPARγ. Recommended for detection of PPARγ1 and PPARγ2 of mouse, rat and human origin by western blot, immunoprecipitation, immunofluorescence, immunohistochemistry (paraffin) and ELISA.

Validation Method

Western blot | Immunocytochemistry

Sample

Control floxed and PPARγ cKO mice bone marrow mesenchymal stem/progenitor cells (BMSCs). IC: Cells grown in chamber slides were fixed with freshly prepared 4% paraformaldehyde containing 0.2% Triton X-100 for 15 min.

Blocking agent

2% BSA for 1 h at room temperature.

Primary incubation

For at least 1 h at room temperature.

Secondary incubation

IC: 1:600 dilution goat anti-mouse IgG-Cy3 or IgG-FITC secondary antibody for 1 h at RT in dark.

Detection

WB: enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech).

IC: Images were acquired using a Nikon TE2000 fluorescence microscope equipped with COOLSNAP Monochrome Camera and processed with Metamorph Imaging System.

References
  1. Cao J, Ou G, Yang N, Ding K, Kream B, Hamrick M, et al. Impact of targeted PPARγ disruption on bone remodeling. Mol Cell Endocrinol. 2015;410:27-34 pubmed publisher